drugset / Trial / NCT02022761
Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma
Phase 1
Completed
32 enrolled
Biota Scientific Management Pty Ltd
Department of Health and Human Services · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a single centre, randomized, double-blind, placebo-controlled, single ascending dose study, in which the safety and pharmacokinetics of laninamivir octanoate administered by inhalation via the TwinCaps® DPI will be assessed in adults with mild or moderate chronic asthma.
Timeline
- Start
- 2013-10
- Primary completion
- 2013-10
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Laninamivir Octanoate | Small molecule | 40 mg | Other |
| Subject | Laninamivir Octanoate | Small molecule | 80 mg | Other |